Nisoldipine coat-core and heart rate response during treatment of hypertension

International Journal of Clinical Practice

Volumn 53, Issue 1, 1999, Pages 65-71

  Zannad, Faiez ^a,b  

^a Ctr Hospitalier Univ de Nancy   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; NISOLDIPINE; NISOLDIPINE COAT CORE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; DRUG BLOOD LEVEL; DRUG FORMULATION; EDEMA; FLUSHING; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; ORAL DRUG ADMINISTRATION; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION; TABLET; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MYOCARDIAL ISCHEMIA; NISOLDIPINE;

EID: 0032970975     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Kannel WB, Kannel C, Daffenbarger RS et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-1494.
2. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J 1986; 7: 279-288.
3. Gillum RF. Epidemiology of resting heart rate in a national sample of men and women: associations with hypertension, coronary heart disease, blood pressure and other cardiovascular risk factors. Am Heart J 1988; 116: 163-174.
4. Ablad B, Bjorkman JA, Güstafsson D et al. The role of sympathetic activity in atherogenesis: effects of beta-blockade. Am Heart J 1988; 116: 322-327.
5. Tsuji H, Venditti FJ, Manders ES et al. Reduced heart rate variability and mortality risk in an elderly cohort: the Framingham Heart Study. Circulation 1994; 90: 878-883.
6. Hjalmarson A, Elmfeldt D. Herlitz J et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-827.
7. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807.
8. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial intervention trials. Am J Cardiol 1986; 57(suppl F): 43-9F.
9. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hum Hypertens 1997; 11: 331-342.
10. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
11. Opie LH, Messerli FM. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995; 92: 1068-1073.
12. Pahor M, Guralnik JM, Corti M et al. Long term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-1197.
13. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
14. Plosker GL, Faulds D. Nisoldipine coat-core: a review of its pharmacology and therapeutic efficacy in hypertension. Drugs, 1996; 52: 232-253.
15. Fleckenstein A. Historical overview: the calcium channels of the heart. Ann NY Acad Sci 1988; 522: 1-15.
16. Godfraind T. Cardioselectivity of calcium antagonists. Drugs Ther 1994; 8: 353-364.
17. Antmann E, Stone PH, Muller JE et al. Calcium channel blocking agents in the treatment of cardiovascular disorders. Ann Intern Med 1980; 93: 875-904.
18. Chatterjee K, Rouleau JL, Parmley WC. Medical management of patients with angina: has first-line management changed? JAMA 1984; 252: 1170-1176.
19. Fisher M, Grotta J. New uses for calcium channel blockers: therapeutic implications. Drugs 1993; 46: 961-975.
20. Weiner DA. Calcium antagonists in the treatment of ischaemic heart disease: angina pectoris. Coron Artery Dis 1994; 5: 14-20.
21. Weiner DA. Calcium channel blockers. Med Clin North Am 1988; 72: 83-115.
22. Godfraind T, Salomone S. Dessy C et al. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol 1992; 20(suppl 5): S34-S41.
23. Kazda S, Garthoff B, Meyer H et al. Pharmacology of a new calcium antagonist compound isobutylmethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylute (Nisoldipine. Bay K5552). Arzneim Forsch Drug Res 1980; 30: 2144-2162.
24. Godfraind T, Eglerne C, Finet M et al. The actions of nifedipine and nisoldipine on the contractile activity of human coronary arteries and human cardiac tissue in vitro. Pharmacol Toxicol 1987; 61: 79-84.
25. Kiowski W, Pfisterer M, Burkart F. Direct vascular and myocardial effects of nisoldipine. Am J Cardiol 1990; 65(suppl G): 65G-69G.
26. van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium channel antagonists: pharmacological aspects. J Hypertens 1993; 11(suppl 1): S3-11.
27. Borchard U. Calcium antagonists in comparison: view of the pharmacologist. J Cardiovasc Pharmacol 1994; 24(suppl 2): S85-S91.
28. Knorr AM. Why is nisoldipine a specific agent in ischemic left ventricular dysfunction? Am J Cardiol 1995; 75(suppl E): 36E-40E.
29. Schall R, Müller FO, Groenewoud G et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic profiles of nisoldipine coat-core tablets in healthy young, healthy elderly and elderly hypertensive volunteers. Drug Invest 1994; 8: 21 -30.
30. Zannad F. Clinical pharmacology of nisoldipine coat core. Am J Cardiol 1995; 75(suppl E): 41E-45E.
31. Schaefer HG, Heinig R. Ahr G et al. Pharmacokinetic-pharmacodynamic modeling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharmacol 1997; 51: 473-480.
32. Bailey DG, Arnold JMO, Strong HA. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993; 54: 589-594.
33. Kleinbloesem CH, Van Brummelin P, Danhof M et al. Rate of increase in plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41: 26-30.
34. Burns JF, Gilbert JC, Pettis PK et al. A multicenter placebo-controlled study of once daily treatment with nisoldipine coat-core in combination with atenolol (ATN) in hypertension (abstract). Am J Hypertens 1994; 7(part 2): 45A.
35. McCarron DA, Gilbert JC, Pettis PK et al. A multicenter placebo-controlled study of once daily treatment with nisoldipine coat-core (NIS) vs. verapamil SR (VER) b.i.d. in hypertension (abstract). Am J Hypertens 1994; 7(part 2): 46A.
36. Müller FOI, Luus HG, Myburgh DP et al. Ambulatory blood pressure monitoring in mild to moderate hypertension treated with a long-acting nisoldipine tablet formulation (abstract). S Afr Med J 1992; 82: 455.
37. Opie LH, Müller FO, Myburgh DP et al. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension. The South African Multicenter ANCHOR Study. Am J Hypertens 1997; 10: 250-260.
38. Ruddy TD, Fodor JG, on behalf of the Canadian Nisoldipine CC Hypertension Trial Group. Nisoldipine CC and Iisinopril alone or in combination for treatment of mild to moderate systemic hypertension. Cardiovasc Drugs Ther 1997; 11: 581-590.
39. Weber MA, Gilbert JC, Pettis PK et al. A multi-center, placebo-controlled study of once daily treatment with nisoldipine coat-core in hypertension (abstract). Am J Hypertens 1994; 7(part 2): 46A.
40. Rousseau MF, Melin J, Benedict CR et al. Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J 1994; 15: 957-964.
41. Fujii Y, Hattori S, Nagami K. The hypotensive effect of nisoldipine: 24 hour blood pressure profile and serial alterations of renal and hormonal function. Curr Ther Res Clin Exp 1994; 55: 93-101.
42. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood pressure. Lancet 1978; 1: 795-797.
43. Kiowski W, Osswald S. Circadian variation of ischemic events. J Cardiovasc Pharmacol 1993; 21(suppl 2): S45-S48.
44. Langan J, Rodriguev-Manas L, Sareli P et al. Nisoldipine CC: clinical experience in hypertension. Cardiology 1997; 88(suppl 1): 56-62.
45. Lasseter KC, Müller FO, Garrett BN et al. Pharmacokinetics, pharmacodynamics, and clinical utility of nisoldipine coat core in the treatment of essential hypertension. Cardiovasc Rev Rep 1996; 17: 28-46.
46. Marazzi P. A study to demonstrate the equivalence in efficacy and safety of once-daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Acta Ther 1996; 22: 23-35.
47. Murray TS. A study to investigate the comparative efficacy and tolerability of nisoldipine coat-core and atenolol in the treatment of mild to moderate hypertension. Br J Clin Pract 1996; 50: 368-371.
48. Rodriguez-Manas L, Guillen F, Caballero JC et al. A comparison of the efficacy, tolerability and effect on quality of life of nisoldipine CC and enalapril in elderly patients with mild-to-moderate hypertension. Acta Therapeut 1996; 22: 89-106.
49. Fodor JG. Comparative efficacy and tolerability of nisoldipine CC and hydrochlorothiazide in mild to moderate hypertension. Int J Clin Pract 1997; 51: 271-275.
50. Seedat YK. The long-term efficacy and tolerability of nisoldipine in patients with mild-to-moderate hypertension. Curr Ther Res 1997; 58: 187-199.
51. Lewis BS. Efficacy and safety of nisoldipine coat-core in the management of angina pectoris, systemic hypertension and ischemic ventricular dysfunction. Am J Cardiol 1995; 75(suppl E): 46E-53E.
52. Glasser SP. Nisoldipine coat core as concomitant therapy in chronic slable angina pectoris. Am J Cardiol 1995; 75(suppl E): 68E-70E.
53. Ruzicka M, Lennen FHH. Relevance of 24 hour blood pressure profile and sympathetic activity for outcome on short-versus long-acting 1,4-dihydropyridines. Am J Hypertens 1995; 9: 86-94.
54. DEFIANT-II Research Group. Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DFFIANT-II study. Eur Heart J 1997; 18: 31-40.
55. Lewis SL, Poole-Wilson PA, for the DEFIANT Study Group. The DEFIANT study of left ventricular function and exercise performance after acute myocardial infarction. Cardiovasc Drugs Ther 1994; 8: 407-418.
56. DEFIANT Research Group. Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients post myocardial infarction: results of the DEFIANT study. Eur Heart J 1992: 13: 1486-1505.
57. Fujii J, Seki A. Compliance and compliance-improving strategies in hypertension: the Japanese experience. J Hypertens 1985; 3(suppl 1): S19-S22.
58. Frishman WH, Rosenberg A, Katz B. Calcium antagonists in the management of systemic hypertension: the impact of sustained-release drug-delivery systems. Coron Artery Dis 1994; 5: 4-13.
59. Kiowski W, Bertel O, Erne P et al. Haemodynamic and reflex mechanisms of acute and chronic antihypertensive therapy with a calcium channel blocker nifedipine. Hypertension 1983; 5(suppl 1): 170-174.
60. Lund-Johansen P. Hemodynamic effects of calcium antagonists in hypertension. High Blood Press Cardiovasc Prev 1994; 3: 367-375.
61. Epstein M. Calcium channel blockers and hypertension: evolving perspectives - 1996. Cardiovasc Drugs Ther 1997; 10: 883-891.
62. Nakaya H, Schwartz A, Millard RW. Reflex chronotropic and inotropic effects of calcium channel-blocking agents in conscious dogs: diltiazem, verapamit and nifedipine compared. Circ Res 1983; 52: 302-311.
63. Brown CAM. Receptors under pressure: an update on baroreceptors. Circ Res 1980; 46: 1-10.
64. Heesch ICM, Miller BM, Thames MD et al. Effects of calcium channel blockers on isolated carotid baroreceptors and baroreflex. Am J Physiol 1983; 245: 653-661.
65. Sleight P. Calcium channel blockers during and after myocardial infarction. Drugs 1996; 51: 216-225.
66. Mayes LC, Horwitz RI, Feinstein AR. A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol 1988; 17: 680-685.
67. Zanchetti A. The calcium channel blocker controversy in perspective. Cardiology 1997; 88(suppl 1): 66-70.
68. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 1995; 155: 2150-2156.
69. Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side. Arch Intern Med 1995; 155: 2157-2161.
70. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995; 123: 888-889.
71. Husten L. Calcium antagonists found 'not guilty'. Lancet 1997; 349: 1818.
72. Staessen JA, Fagard R. Thijs L et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.